IART reports today as short interest eases and analysts hold the line

Integra LifeSciences reported earnings today, October 21, with the positioning that surrounded last week's note having shifted modestly in bears' favour: short interest has edged back from its mid-October peak, analysts have already reset expectations lower, and the stock has dropped a further 3.8% over the past week to $13.33.

The short-side pressure that dominated last week's setup has softened slightly at the margin. Short interest pulled back from 9.4% of the free float a week ago to 9.2% now, a decline of roughly 2% over the week. The absolute level remains elevated. Month-on-month shorts are still up about 4%, so the retreat is trim rather than retreat. The ORTEX short score has drifted down from 59.7 to 58.6 over the past ten sessions, consistent with a modest easing of bearish conviction rather than any reversal. Borrow costs remain low at 0.96%, broadly flat week-on-week after the spike to around 1.55% on October 12. Availability is extremely loose at 1,155%, up from around 983% last week. That means more than eleven shares are available to borrow for every one already lent out, so there is no structural pressure on shorts from the lending market. Options positioning is also mildly call-heavy, with the put/call ratio at 0.15, a touch below its 20-day average of 0.16 and nowhere near the 52-week high of 0.72. Taken together, the positioning picture is one of moderate but fading bearish conviction, not a crowded or squeezable short.

The Street is uniformly cautious. The consensus sits at hold across all seven covering analysts, with a mean price target of $18.00 against a current price of $13.33, implying about 35% nominal upside. That gap looks wide, but the target has been coming in fast. Truist Securities cut its target from $19 to $15 on October 14, keeping a hold. Citi and BMO Capital both trimmed to $15 at the start of October, each maintaining neutral stances. Those moves followed positive revisions from the same firms in July, when targets were raised into the $18 to $19 range after the Q2 print. The reversal in less than three months reflects how quickly the earnings picture has darkened. The bull case centres on the Neurosurgery portfolio, where key product lines delivered double-digit growth and the Instruments segment grew 15.1% year-on-year. Bears point to an adjusted EPS range of $0.40 to $0.45 for the current period, down roughly 23% year-on-year at the midpoint, alongside international revenue falling in the low double digits and gross margin contracting to 62.2%. The factor scores support the bear framing: EPS momentum ranks in the 14th percentile on a 30-day basis and the 26th on a 90-day view, and EPS surprise sits in the 13th percentile, meaning the company has been below-expectations more often than not. The one anomaly is the forward EPS growth rank, which sits in the 97th percentile, suggesting analysts still model a recovery further out even as they cut near-term numbers.

On ownership, the register tells an interesting story of positioning divergence. BlackRock held 13.7% as of September 30, adding around 365,000 shares in the quarter. Invesco added about 355,000 shares over the same period. Rubric Capital Management held 9.97% as of June 30 via a Schedule 13G, up from 6.01% earlier in 2025, a significant passive accumulation at depressed prices. Paradigm Capital filed an amendment in August with no shares owned listed, suggesting it may have exited a prior 5%-plus position. All 13D/G stakes are as last disclosed and holders dropping below 5% may not file again. The insider register has been quiet: the most recent transactions are compensation-related tax withholdings coded as F, not open-market conviction buys or sells.

Retail attention has spiked sharply. The alt data mover for IART shows a Wikipedia and ORTEX page-view z-score of 7.75 as of late September, a reading far above the stock's own recent history. That is a measure of attention rather than a financial indicator, and none of the company's alt data datasets carry a measured lead against reported revenue. The FDA medical devices dataset and clinical trials tracker are available but untested against IART's own figures.

The one prior earnings reaction in the dataset saw the stock fall 1.1% on the day and 2.9% over the following five sessions after the August 2026 print. With the next scheduled event already logged as October 29 in the system, the setup to watch is whether today's actual print and management commentary on the Wound Reconstruction recovery and international stabilisation shift the short-side conviction that has persisted at around 9% of float for much of October.